Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

AIDS

Volumn 24, Issue 4, 2010, Pages 563-572

  Boulle, Andrew ^a   Van Cutsem, Gilles ^a,b   Hilderbrand, Katherine ^a,b   Cragg, Carol ^c   Abrahams, Musaed ^b   Mathee, Shaheed ^c   Ford, Nathan ^a,b   Knight, Louise ^b   Osler, Meg ^a   Myers, Jonny ^a   Goemaere, Eric ^b   Coetzee, David ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Médecins Sans Frontíres ^*  (South Africa)

^c Department of Health   (Denmark)

Author keywords

Antiretroviral therapy; Cohort study; Death registries; HIV; Loss to follow up; Resource limited settings; South Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MORTALITY; PATIENT IDENTIFICATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOUTH AFRICA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; LOST TO FOLLOW-UP; MALE; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 77649266974     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333bfb7     Document Type: Article

References (44)

1. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002; 359:1851-1856.
2. Gilks C, AbouZahr C, Turmen T. HAART in Haiti: evidence needed. Bull World Health Organ 2001; 79:1154-1155.
3. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
4. Mills EJ, Nachega JB, Buchan I,Orbinski J, Attaran A, SinghS, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690.
5. Bekker LG, Orrell C, Reader L, Matoti K, Cohen K, Martell R, et al. Antiretroviral therapy in a community clinic: early lessons from a pilot project. S Afr Med J 2003; 93:458-462.
6. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
7. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-687.
8. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303-2311.
9. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
10. World Health Organization. Antiretroviral therapy in primary healthcare: experience of the Khayelitsha programme in South Africa. Perspectives and Practices in Antiretroviral Treatment. Geneva: World Health Organization; 2003.
11. Western Cape Government Department of Health. Antenatal HIV and syphilis prevalence survey 2006. Cape Town: Western Cape Government Department of Health 2006.
12. Fox RC, Goemaere E. They call it 'patient selection' in Khayelitsha: the experience of Medecins Sans Frontieres-South Africa in enrolling patients to receive antiretroviral treatment for HIV/AIDS. Camb Q Healthc Ethics 2006; 15:302-312
13. National Department of Health. South African National Anti-retroviral Treatment Guidelines. 1st ed. South Africa: National Department of Health; 2004.
14. R testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom 2008; 74 (Suppl 1):S40-S51.
15. Abdullah MF, Young T, Bitalo L, Coetzee N, Myers JE. Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha. S Afr Med J 2001; 91:579-583.
16. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ 2005; 83:489-494.
17. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008; 300:506-507.
18. 1993 revised classification system for HIV infection and expanded surveillance are for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
19. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2006.
20. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanu-wong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-240.
21. Mellors JW, Chow JY. Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks. Clin Infect Dis 2009; 48:473-475.
22. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760.
23. Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, et al. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008; 22:349-356.
24. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive nonnucleoside reverse trans-criptase inhibitor-based regimen. AIDS 2008; 22:2279-2289.
25. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413.
26. Moore RD, Keruly JC. CD4(R) cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441-446.
27. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
28. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/muL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis, 2005;41:361-372.
29. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
30. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
31. R T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
32. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008; 8:89.
33. Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006; 20:1613-1619.
34. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on anti-retroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451.
35. Harries AD, Schouten EJ, Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006; 367:1870-1872.
36. Calmy A, Ford N, Hirschel B, Reynolds SJ, LynenL, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-134.
37. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531.
38. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kam-wendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse tran-scriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
39. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early loss of HIV-infected patients on potent anti-retroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
40. MaskewM, MacPhail P, MenezesC, Rubel D.Lost tofollow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007; 97:853-857.
41. Krebs DW, Chi BH, MulengaY, MorrisM,Cantrell RA, Mulenga L, et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care 2008; 20:311-317.
42. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, Mogorosi M, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 2008; 3:e1725.
43. Bekker LG, Myer L, Orrell C, LawnS, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006; 96:315-320.
44. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.